TWI644686B - Oral poison adsorbent and preparation method thereof - Google Patents

Oral poison adsorbent and preparation method thereof Download PDF

Info

Publication number
TWI644686B
TWI644686B TW105122361A TW105122361A TWI644686B TW I644686 B TWI644686 B TW I644686B TW 105122361 A TW105122361 A TW 105122361A TW 105122361 A TW105122361 A TW 105122361A TW I644686 B TWI644686 B TW I644686B
Authority
TW
Taiwan
Prior art keywords
bamboo
bamboo charcoal
oral
active
polymer material
Prior art date
Application number
TW105122361A
Other languages
Chinese (zh)
Other versions
TW201803552A (en
Inventor
林峯輝
吳宛霖
黃建元
陳昱宏
Original Assignee
財團法人祺華教育基金會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 財團法人祺華教育基金會 filed Critical 財團法人祺華教育基金會
Priority to TW105122361A priority Critical patent/TWI644686B/en
Publication of TW201803552A publication Critical patent/TW201803552A/en
Application granted granted Critical
Publication of TWI644686B publication Critical patent/TWI644686B/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一種口服毒物吸附劑及其製造方法,係可經口投予,進入體內吸附有機毒或無機毒,包括:重金屬、磷以及尿毒素等影響肝腎功能之分子,本案所設計之口服毒物吸附劑,不會沾粘在胃腸道,可以快速排出體外;製作步驟包括:將一竹材置於在400℃到950℃之溫度中,使該竹材碳化,並通入一惰性氣體避免竹材氧化,接著在750℃到1000℃溫度中通入一活化劑,活化該竹材,產生一活性竹炭,接著將該活性竹炭磨成適當大小並與一生物可蛻化高分子材料混合,即製備出該結構為生物可蛻化高分子材料包覆複數活性炭粉末之一活性竹炭微球,該活性竹炭微球即為口服毒物吸附劑。 Oral poison adsorbent and preparation method thereof, which can be administered orally, and adsorb organic poison or inorganic poison, including: heavy metal, phosphorus and urinary toxin, etc., which affect liver and kidney function, and the oral poison adsorbent designed in the present case, Will not stick to the gastrointestinal tract and can be quickly excreted; the preparation steps include: placing a bamboo in a temperature of 400 ° C to 950 ° C, carbonizing the bamboo, and introducing an inert gas to avoid oxidation of the bamboo, followed by 750 An activator is introduced into the temperature from °C to 1000 °C to activate the bamboo material to produce an activated bamboo charcoal, and then the activated bamboo charcoal is ground to an appropriate size and mixed with a biodegradable polymer material to prepare the structure to be bio-available. The deuterated polymer material is coated with one of the activated carbon powder microspheres, and the active bamboo charcoal microsphere is an oral poison adsorbent.

Description

口服毒物吸附劑及其製造方法 Oral poison adsorbent and preparation method thereof

本發明係指一種具多孔隙結構之活性竹炭微球,可有效吸附消化道體內之腎毒素,並可迅速通過腸胃道排出體外之吸附劑及其製造方法。 The invention relates to an active bamboo charcoal microsphere with a porous structure, which can effectively adsorb the nephrotoxin in the digestive tract, and can quickly excrete the adsorbent through the gastrointestinal tract and the manufacturing method thereof.

由於現代人年齡老化、意外、疾病以及職業上的長期接觸、環境污染跟日常飲食,腎毒素及重金屬離子會經由腸胃道、呼吸道以及皮膚進入到人體,進一步與體內蛋白質產生鍵結,而被運送至腎臟過濾清除,因此腎毒素及重金屬離子易堆積在腎絲球以及腎小管,造成腎臟受損,進而降低腎功能,最後演變為慢性腎臟病;慢性腎臟病的患者,失去腎功能之後,身體產生的廢物無法排出體外,漸漸地累積在體內,造成各種器官的毒性,最終需要透過洗腎來將體內毒素代謝,可是洗腎患者日常生活中仍會接觸到許多腎毒素,包括重金屬離子、磷酸鹽類以及尿毒素等,這些腎毒素會對腎臟造成更進一步的破壞,因此,若能開發一種口服劑,能將腎毒素排出體外之,將可加惠腎臟病人,並照顧現代人的健康。 Due to ageing, accidents, illnesses, occupational long-term exposure, environmental pollution and daily diet, kidney toxins and heavy metal ions enter the human body through the gastrointestinal tract, respiratory tract and skin, and are further bonded to the body's proteins. Until the kidney is filtered and removed, nephrotoxin and heavy metal ions are easily accumulated in the kidney glomerulus and renal tubules, causing kidney damage, thereby reducing renal function, and finally evolve into chronic kidney disease; patients with chronic kidney disease, after losing kidney function, the body The waste produced cannot be excreted from the body, gradually accumulates in the body, causing toxicity of various organs. Ultimately, it is necessary to metabolize the toxins in the body through dialysis. However, many kidney toxins are still exposed to the daily life of dialysis patients, including heavy metal ions and phosphoric acid. Salts and urinary toxins can cause further damage to the kidneys. Therefore, if an oral agent can be developed, the nephrotoxin can be excreted from the body, which will benefit the kidney patients and take care of the health of modern people.

尿毒素,包括中分子尿毒素、低分子尿毒素以及高分子尿毒素,尿毒素的產生主要為人類食入之蛋白質,被細菌代謝後轉換為尿毒素之前驅物,藉由大腸吸收進入人體內後轉換為尿毒素,累積在體內之尿毒素會引起慢性腎 臟病,對慢性腎臟病患者而言,不停累積在體內之尿毒素會引發心血管疾病、令慢性腎臟病惡化以及其他併發症產生;尿毒素又以硫酸吲哚酚(indoxyl sulfate)以及對甲酚(p-cresol)在許多文獻中被提及,其累積在身體內會造成許多併發症,間接地使腎功能惡化,最終變成尿毒症。 Urotoxins, including medium molecular urinary toxins, low molecular urea toxins, and macromolecular toxins. The production of urinary toxins is mainly protein ingested by humans. After being metabolized by bacteria, it is converted into a precursor of urinary toxin, which is absorbed into the human body by the large intestine. After conversion to urinary toxins, the accumulation of urinary toxins in the body can cause chronic kidneys Dirty diseases, for patients with chronic kidney disease, the accumulation of urinary toxins in the body can cause cardiovascular disease, worsening chronic kidney disease and other complications; urinary toxins are indoxyl sulfate and contralateral P-cresol has been mentioned in many literatures, and its accumulation in the body causes many complications, indirectly worsening renal function and eventually becoming uremia.

由於慢性腎臟病患者對體內有害物質之排除以及過濾能力有限,而透過食物進入人體之磷酸鹽,無法透過腎臟過濾清除,造成高血磷產生,進一步將導致甲狀腺亢進以及腎性骨病變的發生。 Because patients with chronic kidney disease have limited ability to remove harmful substances from the body and have limited filtration capacity, the phosphate that enters the body through food cannot be cleared by the kidneys, resulting in the production of high blood phosphorus, which will further lead to hyperthyroidism and renal bone lesions.

目前,毒性物質排出體外最普遍之方式是進行血液透析,即俗稱之「洗腎」,藉由洗腎將尿毒素、水分排出體外,以減輕尿毒症狀,並穩定生命徵象,血液透析雖然具備了良好的過濾廢物的能力,但是對於親蛋白質的尿毒素效果不佳,且血液透析在操作上須仰賴醫護人員之專業技術,又,透析過程冗長、價格不菲,在透析治療中及治療後,可能會有抽筋、噁心、疲倦感等,再者,每次治療均有血液流失或血球破壞,易產生貧血等症狀,導致患者產生身心及經濟上的壓力。 At present, the most common way for toxic substances to be excreted in vitro is to perform hemodialysis, commonly known as "dialysis". By washing the kidneys, the urinary toxins and water are excreted to reduce the symptoms of uremia and stabilize the signs of life. Although hemodialysis has Good ability to filter waste, but it is not good for pro-protein urinary toxins, and hemodialysis relies on the professional skills of medical personnel in operation. Moreover, the dialysis process is lengthy and expensive, during and after dialysis treatment. There may be cramps, nausea, fatigue, etc. In addition, each treatment has blood loss or blood cell destruction, which is prone to anemia and other symptoms, resulting in physical and mental and economic stress.

近年來有人在研發對於慢性腎臟病人吸附體內毒素的口服藥物,習知有兩種口服吸附劑,其原料主要為瀝青與植物炭材,利用瀝青製備口服吸附劑時,首先需去除其內所含有之雜質及重金屬等物質,再加工成球狀顆粒,其製備工程繁複,成本高,因此價格昂貴,對需長期服用之病人造成經濟上的負擔;而藉由植物炭材製備之口服吸附劑,是將植物炭材研磨成細微粉末,其難以藉由腸胃道蠕動排出,而易沾附於腸壁上,使得吸附毒物之口服藥物在體內的停留時間較長,進而刺激腸胃道,且不利於毒素的排出。 In recent years, some people have been developing oral drugs for the absorption of toxins from chronic kidney patients. It is known that there are two kinds of oral adsorbents, the raw materials of which are mainly asphalt and plant carbon materials. When using asphalt to prepare oral adsorbents, the first need to remove them. The impurities and heavy metals are processed into spherical particles, which are complicated in preparation and high in cost, so they are expensive, and cause an economic burden on patients who need to take long-term use; and oral adsorbents prepared by plant carbon materials, The plant charcoal material is ground into a fine powder, which is difficult to be discharged by the gastrointestinal motility, and is easy to adhere to the intestinal wall, so that the oral drug adsorbing the poison has a longer residence time in the body, thereby stimulating the gastrointestinal tract, and is not conducive to Excretion of toxins.

緣此之故,申請人鑑於習知技術之缺失,開發一種透過口服,進入體內吸附重金屬、尿毒素以及磷,且具有吸附性良好並快速排出體外的口服毒物吸附劑,以解決目前的問題。 For this reason, the Applicant has developed an oral toxic adsorbent that is orally administered into the body to adsorb heavy metals, urinary toxins, and phosphorus, and which has good adsorptivity and is rapidly excreted from the body, in order to solve the current problem, in view of the lack of the prior art.

本發明之目的在提供一種口服毒物吸附劑,係可經由口服投予,進入腸胃道吸附有機毒或無機毒,包括:重金屬、磷、尿毒素、影響肝腎功能之分子、誤食之毒物或致病原等,並且可以快速排出體外,不在胃腸道沾粘;如此,不但可應用於健康人以及慢性腎病患者日常生活的毒物排除,更可可應用在化學品中毒病人的緊急治療藥物投予,藉以減緩毒物在體內的擴散。 The object of the present invention is to provide an oral toxicant adsorbent which can be administered orally to enter the gastrointestinal tract to adsorb organic or inorganic toxicants, including: heavy metals, phosphorus, urinary toxins, molecules affecting liver and kidney function, poisons ingested or caused Pathogens, etc., and can be quickly excreted from the body, not sticky in the gastrointestinal tract; thus, not only can be used for the elimination of toxic substances in the daily life of healthy people and patients with chronic kidney disease, but also can be applied to emergency treatment drugs for patients with chemical poisoning. Slow down the spread of poisons in the body.

為達上述之目的,本發明選用具多孔性及吸附性之竹炭進行口服吸附劑之製造,製作方法在於:先將一竹材裁切,並清淨後放入一高溫炭化爐中;接著將該高溫炭化爐升溫至400℃至950℃,進行炭化程序;接著持續於該高溫炭化爐中維持其溫度在750℃至1000℃,進行竹炭活化,產生一活性竹炭;將該活性竹炭冷卻、清洗乾淨並使之乾燥;再將該活性竹炭研磨成一活性竹炭粉末,接著將該活性竹炭粉末與一生物可蛻化高分子材料混合,進一步將混有該生物可蛻化高分子材料之活性竹炭粉末滴到0.01-10%的交聯溶液中,即製備其結構為該生物可蛻化高分子材料包覆複數活性竹炭粉末之一活性竹炭微球,該活性竹炭微球即為本發明之口服毒物吸附劑。 In order to achieve the above object, the present invention selects a porous and adsorbable bamboo charcoal for the manufacture of an oral adsorbent, which is prepared by first cutting a bamboo material, cleaning it, and placing it in a high temperature carbonization furnace; The carbonization furnace is heated to 400 ° C to 950 ° C to carry out a carbonization process; then, the temperature is maintained at 750 ° C to 1000 ° C in the high temperature carbonization furnace to activate bamboo charcoal to produce an activated bamboo charcoal; the activated bamboo charcoal is cooled and cleaned. Drying the activated bamboo charcoal into an active bamboo charcoal powder, and then mixing the active bamboo charcoal powder with a biodegradable polymer material, further dropping the active bamboo charcoal powder mixed with the biodegradable polymer material 0.01-10% of the cross-linking solution, that is, the active bamboo charcoal microsphere prepared by coating the bio-deuterated polymer material with a plurality of active bamboo charcoal powder, the active bamboo charcoal microsphere is the oral poison adsorbent of the invention .

本發明之另一目的在於避免習知口服藥物在腸胃道沾粘之現象產生,製程中將該活性竹炭粉末混合天然高分子物質之該生物可蛻化高分子材料,如此吸附腎毒素之口服毒物吸附劑可快速通過腸胃道並排出體外,避免腸 胃道沾黏,同時該生物可蛻化高分子材料之表面具有複數孔洞,可加強該口服毒物吸附劑之吸附能力。 Another object of the present invention is to avoid the phenomenon that the conventional oral drug is adhered in the gastrointestinal tract, and the active bamboo charcoal powder is mixed with the natural high molecular substance of the biodegradable polymer material in the process, thereby adsorbing the oral poison of the nephrotoxin. The adsorbent can quickly pass through the gastrointestinal tract and excrete from the body, avoiding the intestines The gastric tract is sticky, and the surface of the biodegradable polymer material has a plurality of pores, which can enhance the adsorption capacity of the oral toxic adsorbent.

501‧‧‧竹材 501‧‧‧Bamboo

502‧‧‧清洗液 502‧‧‧ cleaning solution

503‧‧‧炭化竹材 503‧‧‧Carbonized bamboo

505‧‧‧活性竹炭 505‧‧‧Active bamboo charcoal

507‧‧‧活性竹炭粉末 507‧‧‧Active bamboo charcoal powder

509‧‧‧活性竹炭微球 509‧‧‧Active bamboo charcoal microspheres

509’‧‧‧正電竹炭微球 509’‧‧‧正电竹炭微球

509”‧‧‧負電竹炭微球 509”‧‧‧negative bamboo charcoal microspheres

101‧‧‧高溫炭化爐 101‧‧‧High temperature carbonization furnace

102‧‧‧生物可蛻化高分子材 料 102‧‧‧Bio-degradable polymer materials material

105‧‧‧活化劑 105‧‧‧activator

103‧‧‧惰性氣體 103‧‧‧Inert gas

107‧‧‧研磨元件 107‧‧‧Abrasive components

S1~S6‧‧‧步驟 S1~S6‧‧‧Steps

T‧‧‧腎毒素 T‧‧‧ kidney toxin

B1‧‧‧口腔緩衝溶液 B1‧‧‧ oral buffer solution

B2‧‧‧胃液緩衝溶液 B2‧‧‧ gastric juice buffer solution

B3‧‧‧小腸緩衝溶液 B3‧‧‧Intestinal buffer solution

B4‧‧‧大腸緩衝溶液 B4‧‧‧ Large Intestine Buffer Solution

第1圖為本發明之製程方塊流程圖。 Figure 1 is a flow chart of a process block of the present invention.

第2圖為本發明之剖面結構示意圖。 Figure 2 is a schematic cross-sectional view of the present invention.

第3圖為本發明之掃描式電子顯微鏡(SEM)影像(27x)。 Figure 3 is a scanning electron microscope (SEM) image (27x) of the present invention.

第4圖為本發明之掃描式電子顯微鏡(SEM)影像(350x)。 Figure 4 is a scanning electron microscope (SEM) image (350x) of the present invention.

第5圖為本發明之X射線繞射比較圖。 Figure 5 is a comparison diagram of X-ray diffraction of the present invention.

第6圖為本發明之亞甲基藍水溶液吸附能力結果示意圖。 Fig. 6 is a view showing the results of the adsorption capacity of the methylene blue aqueous solution of the present invention.

第7圖為本發明之對碘水溶液吸附能力結果示意圖。 Figure 7 is a schematic view showing the results of the adsorption capacity of the aqueous solution of iodine according to the present invention.

第8圖為本發明之帶正電竹炭微球電子顯微鏡(SEM)影像(30X)。 Figure 8 is an electron microscope (SEM) image (30X) of a positively charged bamboo charcoal microsphere of the present invention.

第9圖為本發明之帶負電竹炭微球電子顯微鏡(SEM)影像(65X)。 Figure 9 is an electron microscope (SEM) image (65X) of a negatively charged bamboo charcoal microsphere of the present invention.

第10圖為本發明之實施例3流程示意圖。 Figure 10 is a schematic flow chart of Embodiment 3 of the present invention.

第11A圖為本發明實施例3之重金屬鉛吸附結果。 Fig. 11A is a graph showing the results of adsorption of heavy metal lead in Example 3 of the present invention.

第11B圖為本發明實施例3之重金屬鉻吸附結果。 Fig. 11B is a graph showing the results of adsorption of heavy metal chromium according to Example 3 of the present invention.

第11C圖為本發明實施例3之磷酸鹽吸附結果。 Fig. 11C is a graph showing the results of phosphate adsorption of Example 3 of the present invention.

第11D圖為本發明實施例3之尿毒素吲哚吸附結果。 Fig. 11D is a view showing the adsorption of urinary toxin oxime in Example 3 of the present invention.

第11E圖為本發明實施例3之尿毒素對甲酚吸附結果。 Fig. 11E is a graph showing the results of adsorption of urinary toxin to cresol according to Example 3 of the present invention.

請參閱第1、2圖所示,本發明提供一種口服毒物吸附劑及其製造方法,依據下列步驟流程進行:首先,將一竹材501裁切成約10cm×5cm之大小,清洗乾淨後放入一高溫炭化爐101中,進行步驟S1,真空抽氣;接著進行步驟S2,將該高溫炭化爐101之溫度以5-20℃/min升溫速度升溫至400℃至950℃,其中以600℃至900℃為最佳,將切割後之該竹材501置於其中30至60分鐘,令該竹材501炭化,在升溫過程中以速度100ml/min至400ml/min通入一惰性氣體103於該高溫炭化爐101中,其中以100ml/min之速度為最佳,該惰性氣體103可為氮氣或氬氣,令該竹材501在無氧的環境下燃燒炭化,產生一炭化竹材503;接著進行步驟S3,將該炭化竹材503持續將該高溫炭化爐101維持在750℃至1000℃,以900℃為最佳溫度,並以100ml/min至400ml/min之速度通入一活化劑105,進行竹炭活化,該活化劑105可為二氧化碳或水蒸氣,通入速度以100ml/min為最佳,作用時間為1至2小時,即可產生一活性竹炭505;接著進行步驟S4,將該活性竹炭505冷卻,用一清洗液502將其清洗乾淨並使之乾燥;進行步驟S5,利用一研磨元件107,將該活性竹炭505磨成適當大小,其中該研磨元件107以100-230mesh為最佳,分選出50微米至1000微米之一活性竹炭粉末507;進行步驟S6,將研磨後之該活性竹炭粉末507與一生物可蛻化高分子材料102混和,其重量比為1:2~1:5,以1:3為最佳,藉由攪拌使該活性炭粉末507均勻分散於該生物可蛻化高分子材料102中,進一步將混有該生物可蛻化高分子材料102之活性竹炭粉末507滴到0.01-10%的交聯溶液中,本發明之交聯溶液為1M NaOH溶液,即製備出其結構為該生物可蛻化高分子材料102包覆複數活性竹炭粉末507之一活性竹炭微球509,該活性竹炭微球 509即為本發明之口服毒物吸附劑,該活性竹炭微球509之直徑大小約100微米至2000微米(請參閱第2圖所示)。 Referring to Figures 1 and 2, the present invention provides an oral poison adsorbent and a method for producing the same, which are carried out according to the following steps: First, a bamboo material 501 is cut into a size of about 10 cm × 5 cm, cleaned and placed. In a high temperature carbonization furnace 101, step S1 is performed, vacuum evacuation; then step S2 is performed, and the temperature of the high temperature carbonization furnace 101 is raised to 400 ° C to 950 ° C at a temperature increase rate of 5-20 ° C / min, wherein 600 ° C to 600 ° C 900 ° C is the best, the cut bamboo 501 is placed therein for 30 to 60 minutes, the bamboo 501 is carbonized, and an inert gas 103 is introduced into the high temperature carbonization at a speed of 100 ml/min to 400 ml/min during the heating process. In the furnace 101, wherein the speed is preferably 100 ml/min, the inert gas 103 may be nitrogen or argon, and the bamboo 501 is burned and carbonized in an oxygen-free environment to produce a carbonized bamboo 503; then, step S3 is performed. The carbonized bamboo 503 is continuously maintained at 750 ° C to 1000 ° C, at an optimum temperature of 900 ° C, and an activator 105 is introduced at a rate of 100 ml / min to 400 ml / min to activate bamboo charcoal. The activator 105 can be carbon dioxide or steamed The inlet speed is preferably 100 ml/min, and the action time is 1 to 2 hours, so that an activated bamboo charcoal 505 is produced; then, in step S4, the activated bamboo charcoal 505 is cooled, and the cleaning liquid is cleaned with a cleaning liquid 502. Drying; performing step S5, grinding the active bamboo charcoal 505 into an appropriate size by using a grinding element 107, wherein the grinding element 107 is preferably 100-230 mesh, and sorting one of 50 micrometers to 1000 micrometers of activated bamboo charcoal powder 507 In step S6, the activated bamboo charcoal powder 507 after grinding is mixed with a biodegradable polymer material 102 in a weight ratio of 1:2 to 1:5, preferably 1:3, by stirring. The activated carbon powder 507 is uniformly dispersed in the biodegradable polymer material 102, and the active bamboo charcoal powder 507 mixed with the biodegradable polymer material 102 is further dropped into 0.01-10% of a crosslinking solution, and the present invention The cross-linking solution is a 1M NaOH solution, that is, the active bamboo charcoal microsphere 509 is prepared by coating the bio-deuterated polymer material 102 with a plurality of active bamboo charcoal powder 507. 509 is the oral toxic adsorbent of the present invention, and the active bamboo charcoal microsphere 509 has a diameter of about 100 micrometers to 2000 micrometers (see Fig. 2).

上述製程步驟中該竹材501可為成熟群之孟宗竹、鳳尾竹或淡竹等任何種類竹子之群體,本發明係選自四年生以上之孟宗竹材;該清洗液502可為酸性水溶液、鹼性水溶液以及有機溶劑等;該生物可蛻化高分子材料102可為:1%~3%(W/V)之幾丁聚醣(chitosan)、玉米澱粉、甲基纖維素、明膠、褐藻膠、聚糊精以及海藻酸(alginate)等任何天然高分子、天然高分子改良及任何合成高分子等單一或任意組成之群組。 In the above process step, the bamboo material 501 may be a group of any kind of bamboo such as Mengzong bamboo, phoenix bamboo or light bamboo of the mature group, and the invention is selected from Mengzong bamboo material of four or more years; the cleaning liquid 502 may be an acidic aqueous solution or an alkaline aqueous solution. And an organic solvent or the like; the biodegradable polymer material 102 can be: 1% to 3% (w/v) chitosan (chitosan), corn starch, methyl cellulose, gelatin, alginate, poly Any group of single or arbitrary components such as dextrin and alginate, such as natural polymers, natural polymer improvements, and any synthetic polymers.

請參閱第3、4圖所示,本發明之該活性竹炭微球509呈現球狀,以SEM檢測該活性竹炭微球509之表面形貌,該SEM影像(27x)顯示該活性竹炭微球509外觀為表面粗糙之完整球型,大小約1.5毫米,且表面呈現不規則之粗糙坑洞,將該活性竹炭微球509剖開,其SEM影像顯示(350x)顯示該活性竹炭微球509內部為多孔隙類海綿狀之結構(請參閱第4圖所示)。 Referring to Figures 3 and 4, the active bamboo charcoal microspheres 509 of the present invention are spherical, and the surface topography of the active bamboo charcoal microspheres 509 is detected by SEM. The SEM image (27x) shows the active bamboo charcoal microspheres 509. The appearance is a complete spherical shape with a rough surface, the size is about 1.5 mm, and the surface presents irregular rough holes. The active bamboo charcoal microspheres 509 are cut open, and the SEM image shows (350x) that the inside of the active bamboo charcoal microspheres 509 is A porous, spongy structure (see Figure 4).

該活性竹炭微球509能通過食道,係可經口投進入腸胃道內,並具有吸附體內有機毒或無機毒之特性,其有機毒或無機毒包括:重金屬、磷、化學品、細菌性病毒、消化性毒素、其他有機性廢物、腸內滯留氣體之物體、生理代謝物、影響肝腎功能之分子以及誤食之毒物或致病原等,該活性竹炭微球509吸附上述物質後可透過腸胃道蠕動排出體外。 The active bamboo charcoal microsphere 509 can pass through the esophagus and can be orally administered into the gastrointestinal tract, and has the characteristics of adsorbing organic or inorganic toxicity in the body, and the organic or inorganic toxicity includes heavy metals, phosphorus, chemicals, and bacterial viruses. , digestive toxins, other organic wastes, objects trapped in the intestines, physiological metabolites, molecules affecting liver and kidney function, and poisons or pathogens that are inadvertently eaten, the active bamboo charcoal microspheres 509 can absorb the above substances and pass through the stomach The motility is excreted from the body.

使用比表面積分析儀(BET)測量竹炭活化前後比表面積之差異,由表一所示,活化前竹炭(即炭化竹材503)之比表面積為195.82±11.5m2/g,當該炭化竹材503在900℃下,通入該活化劑105進行活化後,其比表面積提高2.7倍,為534.39±32.5m2/g。 The specific surface area analyzer (BET) was used to measure the difference in specific surface area before and after activation of bamboo charcoal. As shown in Table 1, the specific surface area of bamboo charcoal (ie, charred bamboo 503) before activation was 195.82±11.5 m 2 /g, when the charred bamboo 503 was in At 900 ° C, after activation with the activator 105, the specific surface area was increased by 2.7 times to 534.39 ± 32.5 m 2 /g.

請參閱第5圖所示,利用X射線繞射(XRD)觀察活化之該活性竹炭505(請參閱第5A圖所示)以及未活化之竹碳(請參閱第5B圖所示)結晶結構,該活性竹炭505與未活化之竹炭相比,其結晶構造、顯微結構以及孔隙度皆未改變,且經活化步驟,該活性竹炭505相較於未活化之竹炭具有高孔隙及高吸附力,且表面具有官能基(請參閱附件1),如此對腎毒素之吸附具有良好之效果。 Referring to Figure 5, X-ray diffraction (XRD) is used to observe the activated bamboo charcoal 505 (see Figure 5A) and the unactivated bamboo carbon (see Figure 5B). Compared with the unactivated bamboo charcoal, the active bamboo charcoal 505 has no change in crystal structure, microstructure and porosity, and the activated bamboo charcoal 505 has high porosity and high adsorption force compared with the unactivated bamboo charcoal. The surface has a functional group (see Annex 1), which has a good effect on the adsorption of nephrotoxin.

發明人將該活性竹炭微球509進行吸附能力測驗,如亞甲基藍、碘、金屬離子、磷酸鹽以及尿毒素等。 The inventors performed the adsorption capacity test on the active bamboo charcoal microspheres 509, such as methylene blue, iodine, metal ions, phosphate, and urinary toxin.

實施例1 Example 1

請參閱第6圖所示,本實施例係進行該口服毒物吸附劑之亞甲基藍水溶液吸附測試,首先配置濃度20ppm之亞甲基藍水溶液,將10mg之該活性竹炭微球509、未活化之炭化竹材503以及市售口服吸附劑(對照組)加入亞甲基藍水溶液中浸泡24小時,之後使用分光光度計測量亞甲基藍水溶液濃度之變化;24小時後,可發現本發明之該活性竹炭微球509對亞甲基藍有良好之吸附能力。 Referring to FIG. 6 , in this embodiment, the adsorption test of the methylene blue aqueous solution of the oral poison adsorbent is performed by first disposing a methylene blue aqueous solution having a concentration of 20 ppm, 10 mg of the active bamboo charcoal microsphere 509, unactivated carbonized bamboo 503, and the city. The commercially available oral adsorbent (control group) was immersed in a methylene blue aqueous solution for 24 hours, and then the change in the concentration of the methylene blue aqueous solution was measured using a spectrophotometer; after 24 hours, the active bamboo charcoal microsphere 509 of the present invention was found to have a good adsorption capacity for methylene blue. .

實施例2 Example 2

請參閱第7圖所示,本實施例係進行該口服毒物吸附劑之碘吸附測試,根據日本工業規範JISK1474(19991),針對活性碳之檢測方式進行測量活性碳對碘的吸附,首先將該活性竹炭微球509、未活化之炭化竹材503以及市售口 服吸附劑(對照組)加入測試用標準碘水溶液中,測量碘被該活性竹炭微球509所吸附量;其結果顯示三組皆有良好之吸附效果。 Referring to FIG. 7 , in this embodiment, the iodine adsorption test of the oral toxic adsorbent is performed, and the adsorption of activated carbon on iodine is measured according to the Japanese Industrial Standard JISK1474 (19991). Active bamboo charcoal microspheres 509, unactivated charred bamboo 503 and commercially available mouth The adsorbent (control group) was added to the standard aqueous iodine solution for testing, and the amount of iodine adsorbed by the active bamboo charcoal microsphere 509 was measured; the results showed that all three groups had good adsorption effects.

從實施例1、2可知本發明具有與市售之口服吸附劑吸附效果相當,甚至具更佳之吸附力。 It can be seen from Examples 1 and 2 that the present invention has an adsorption effect comparable to that of a commercially available oral adsorbent, and even has a better adsorption force.

實施例3、4 Example 3, 4

請參閱第8、9圖所示,於實施例3、4中測試該活性竹炭粉末507包覆不同之該生物可蛻化高分子材料102,於模擬腸胃道環境對腎毒素之吸附能力,其中腎毒素包括:鉛(Pb)、鉻(Cr)、磷酸鹽(PO4 3-)、吲哚(Indole)以及對甲酚(p-Cresol);首先將該等活性竹炭粉末507分別混合添加幾丁聚醣(Chitosan)之該生物可蛻化高分子材料102,形成帶正電之一正電竹炭微球509’(請參閱8圖所示),以及添加海藻酸(Alginate)之該生物可蛻化高分子材料102,形成帶負電之一負電竹炭微球509”(請參閱9圖所示),從第8以及9圖中可發現,包覆不同之該生物可蛻化高分子材料102之該等活性竹炭微球509其外形仍為圓形顆粒,且表面呈現多孔洞之形貌,添加幾丁聚醣及海藻酸之該生物可蛻化高分子材料102令該活性竹炭微球509表面具有不同官能基;幾丁聚醣之該生物可蛻化高分子材料102之該正電竹炭微球509’其表面具有NH3 +官能基,可與帶負電之離子結合(如磷離子),接著再與帶正電之離子(如鈣離子)結合後形成結晶,並透過腸胃道蠕動排出體外;又,包覆海藻酸之該生物可蛻化高分子材料102之該負電竹炭微球509”其表面具有COO-官能基,先與帶正電之離子(如鈣離子)結合,再與帶負電之離子(磷離子)結合,進一步形成結晶,透過腸胃道蠕動排出體外。 Referring to Figures 8 and 9, in the Examples 3 and 4, the active bamboo charcoal powder 507 is coated with the biodegradable polymer material 102 to simulate the adsorption capacity of the gastrointestinal environment to the nephrotoxin. The nephrotoxin includes: lead (Pb), chromium (Cr), phosphate (PO 4 3- ), indole, and p-cresol; firstly, the active bamboo charcoal powder 507 is separately mixed and added. Chitosan's biodegradable polymer material 102 forms a positively charged positive charcoal microsphere 509' (see Figure 8), and the addition of alginate to the organism. The deuterated polymer material 102 forms a negatively charged negatively charged bamboo charcoal microsphere 509" (see Figure 9). It can be found from Figures 8 and 9 that the biodegradable polymer material 102 is coated differently. The active bamboo charcoal microspheres 509 are still round in shape and have a porous surface morphology. The biodegradable polymer material 102 is added with chitosan and alginic acid to make the active bamboo charcoal microspheres 509 The surface has different functional groups; the bio-deuterated polymer material 102 of the chitosan is the positive electric bamboo charcoal micro 509 'having a surface with NH 3 + functional groups can be combined with negatively charged ions of (e.g., phosphorus ions), followed by the formation of crystalline after recombined with positively charged ions of (e.g., calcium), and excreted through the gastrointestinal tract motility; Further, the negatively-charged bamboo charcoal microsphere 509" of the biodegradable polymer material 102 coated with alginic acid has a COO - functional group on its surface, first combined with positively charged ions (such as calcium ions), and then negatively charged. The ions (phosphorus ions) combine to form crystals further and are excreted through the gastrointestinal motility.

實施例3-腎毒素吸附測試1 Example 3 - Nephrotoxin adsorption test 1

請參閱第10圖所示,首先,分別取0.05g之該正、負電竹炭微球509’、509”,並分別浸入含有一腎毒素T之一口腔緩衝溶液B15分鐘,該口腔緩衝溶液B1之pH質為6.5,5分鐘後吸取該口腔緩衝溶液B1測其吸光值,檢測該口腔緩衝溶液B1中該腎毒素T被吸附量,接著,將含有該腎毒素T之一胃液緩衝溶液B2加入上述之該正、負電竹炭微球509’、509”中,該胃液緩衝溶液B2之pH值為2,浸泡2小時後取出該胃液緩衝溶液B2,測試其吸光值,接著,將含有該腎毒素T之一小腸緩衝溶液B3加入上述之該正、負電竹炭微球509’、509”中,該小腸緩衝溶液B3之pH值為7.5,浸泡5小時後取出該小腸緩衝溶液B3,測試其吸光值,最後,將含有該腎毒素T之一大腸緩衝溶液B4加入上述之該正、負電竹炭微球509’、509”中,該大腸緩衝溶液B4之pH值為8,浸泡24小時後取出該大腸緩衝溶液B4,測試其吸光值。 Referring to FIG. 10, first, 0.05 g of the positive and negative electric bamboo charcoal microspheres 509', 509" are respectively taken and immersed in an oral buffer solution B containing one nephrotoxin T for 15 minutes, and the oral buffer solution B1 is used. The pH is 6.5. After 5 minutes, the oral buffer solution B1 is taken to measure the absorbance, and the amount of the toxin T adsorbed in the oral buffer solution B1 is detected. Then, the gastric juice buffer solution B2 containing the nephrotoxin T is added to the above. In the positive and negative electric bamboo charcoal microspheres 509', 509", the gastric juice buffer solution B2 has a pH of 2, and after soaking for 2 hours, the gastric juice buffer solution B2 is taken out, and the absorbance value thereof is tested, and then the nephrotoxin T is contained. One small intestinal buffer solution B3 is added to the above-mentioned positive and negative electric bamboo charcoal microspheres 509', 509", the pH value of the small intestinal buffer solution B3 is 7.5, and after immersing for 5 hours, the small intestinal buffer solution B3 is taken out, and the absorbance is tested. Finally, the large intestine buffer solution B4 containing the nephrotoxin T is added to the positive and negative electric bamboo charcoal microspheres 509', 509", the pH value of the large intestine buffer solution B4 is 8, and the large intestine buffer is taken out after soaking for 24 hours. Solution B4, test its suction Value.

於本實施例中,測試尿毒素-吲哚(Indole)以及對甲酚(p-Cresol)時,因尿毒素僅出現在小腸以及大腸中,因此先將0.05g之該正、負電竹炭微球509’、509”浸泡該口腔緩衝溶液B15分鐘,5分鐘後去除該口腔緩衝溶液B1,接著加入該胃液緩衝溶液B2並浸泡2小時,2小時後去除該胃液緩衝溶液B2,接著加入含有該腎毒素T之該小腸緩衝溶液B3,浸泡5小時後取出該小腸緩衝溶液B3,測試其吸光值,最後加入含有該腎毒素T之大腸緩衝溶液B4於上述該正、負電竹炭微球509’、509”中,浸泡24小時後取出該大腸緩衝溶液B4,測試其吸光值。 In the present embodiment, when testing uremic toxin-indole (p-Cresol), since urinary toxin only appears in the small intestine and the large intestine, 0.05 g of the positive and negative electric bamboo charcoal microspheres are first introduced. 509', 509" soak the oral buffer solution B for 15 minutes, remove the oral buffer solution B1 after 5 minutes, then add the gastric juice buffer solution B2 and soak for 2 hours, remove the gastric juice buffer solution B2 after 2 hours, and then add the kidney containing The intestinal buffer solution B3 of the toxin T is taken out for 5 hours, the small intestinal buffer solution B3 is taken out, the absorbance value thereof is tested, and finally the large intestine buffer solution B4 containing the nephrotoxin T is added to the positive and negative electric bamboo charcoal microspheres 509', 509. In the middle, after immersing for 24 hours, the large intestine buffer solution B4 was taken out and tested for absorbance.

請參閱第11A-E圖所示,橫座標為該正、負電竹炭微球509’、509”分別於不同緩衝溶液中吸收該等腎毒素T之結果,而縱座標為每公克(g)之該正、負電竹炭微球509’、509”所能吸收多少毫克(mg)之該腎毒素T;其中重金屬鉛在4種緩衝液之吸引效果皆具有統計意義(請參閱第11A圖所示),重金屬鉻在該小、 大腸緩衝液B3、B4之吸引效果皆具有統計意義(請參閱第11B圖所示),磷酸鹽在該口腔、胃緩衝液B1、B2之吸引效果皆具有統計意義(請參閱第11C圖所示),吲哚在該小、大腸緩衝液B3、B4之吸引效果皆具有統計意義(請參閱第11D圖所示),對甲酚在該小、大腸緩衝液B3、B4之吸引效果皆具有統計意義(請參閱第11E圖所示),綜上所述,該正、負電竹炭微球509’、509”對於各種該腎毒素T皆有良好的吸收功效。 Referring to Figures 11A-E, the abscissa is the result of the absorption of the nephrotoxin T by the positive and negative bamboo charcoal microspheres 509', 509" in different buffer solutions, and the ordinate is per gram (g). How many milligrams (mg) of the nephrotoxin T can be absorbed by the positive and negative bamboo charcoal microspheres 509', 509"; the attraction effect of heavy metal lead in the four buffers is statistically significant (see Figure 11A). , heavy metal chromium is small, The attracting effects of the large intestine buffers B3 and B4 are statistically significant (see Figure 11B). The attraction of phosphate in the oral and gastric buffers B1 and B2 is statistically significant (see Figure 11C). ), the attraction effects of the small and large intestine buffers B3 and B4 are statistically significant (see Figure 11D), and the attraction effects of p-cresol in the small and large intestine buffers B3 and B4 are statistically significant. The meaning (see Fig. 11E), in summary, the positive and negative bamboo charcoal microspheres 509', 509" have good absorption effects for various nephrotoxin T.

為達到良好吸附該腎毒素T功效,係可選自以一種或多種該生物可蛻化高分子材料102混合之該活性竹炭微球509,混合搭配使用,其中添加海藻酸之該生物可蛻化高分子材料102所形成之該負電竹炭微球509”與添加幾丁聚醣之該生物可蛻化高分子材料102所形成之該正電竹炭微球509’,其混合使用比例為2:1至5:1,尤以3:1為最佳,如此可提升吸附功效。 In order to achieve good adsorption of the rennet toxin T, the active bamboo charcoal microspheres 509 mixed with one or more of the biodegradable polymer materials 102 may be selected and used in combination, wherein the biodegradable acid may be deuterated. The negatively-charged bamboo charcoal microspheres 509 ′′ formed by the polymer material 102 and the positively-charged bamboo charcoal microspheres 509 ′ formed by the biodegradable polymer material 102 added with chitosan have a mixing ratio of 2:1. Up to 5:1, especially 3:1 is the best, which can improve the adsorption efficiency.

綜上所述,該活性竹炭微球509可經口投進入腸胃道內,因該活性竹炭微球509具有多數孔洞,且因受過活化,其表面具有多種官能基,可吸收人體內之毒性物質,又,於製程時該活性竹炭粉末507混合不同種類之天然高分子物質之該生物可蛻化高分子材料102,令該活性竹炭微球509可透過腸胃道之蠕動迅速排出體外,再者該活性竹炭微球509之原料為竹子,其原料取得容易,製程簡單,又具有吸附腸胃道之毒素與快速排出體外之功能;反觀習知之口服吸附具有製程繁瑣,價格昂貴,且口服後易沾附於腸胃道壁上,難以藉由腸胃道之蠕動排出體外等諸多缺點。 In summary, the active bamboo charcoal microspheres 509 can be administered orally into the gastrointestinal tract, because the active bamboo charcoal microspheres 509 have a plurality of pores, and because of activation, the surface has a plurality of functional groups, which can absorb toxic substances in the human body. Further, during the process, the active bamboo charcoal powder 507 is mixed with the different kinds of natural high molecular substances of the biodegradable polymer material 102, so that the active bamboo charcoal microspheres 509 can be quickly excreted through the gastrointestinal tract peristalsis. The raw material of the active bamboo charcoal microsphere 509 is bamboo, the raw material is easy to obtain, the process is simple, and the function of adsorbing the toxin of the gastrointestinal tract and the rapid excretion of the body is obtained; in contrast, the oral adsorption of the conventional method has a complicated process, is expensive, and is easy to adhere after oral administration. On the wall of the gastrointestinal tract, it is difficult to excrete the body by the peristalsis of the gastrointestinal tract.

上列詳細說明係針對本發明之可行實施例之具體說明,惟該實施例並非用以限制本發明之專利範圍,凡未脫離本發明技藝精神所為之等效實施或變更,均應包含於本案之專利範圍中。 The detailed description of the preferred embodiments of the present invention is not intended to limit the scope of the present invention, and the equivalent implementations or modifications of the present invention should be included in the present invention. In the scope of patents.

Claims (9)

一種口服毒物吸附劑之結構,係由一幾丁聚醣之生物可蛻化高分子材料包覆一活性竹碳粉末形成一表面官能基帶正電之正電活性竹碳微球結構,其中該活性竹炭粉末與該幾丁聚醣之生物可蛻化高分子材料之混合重量比為1:2至1:5,並經口投吸附腸胃道之毒性物質,再由腸道排出體外。 The structure of an oral toxic adsorbent is characterized in that a bio-deuterated polymer material of a chitosan is coated with an active bamboo carbon powder to form a positively functional positively charged bamboo carbon microsphere structure with a surface functional group, wherein The mixed weight ratio of the active bamboo charcoal powder to the chitosan biodegradable polymer material is 1:2 to 1:5, and the toxic substances in the gastrointestinal tract are orally administered by the oral cavity, and then excreted from the intestinal tract. 如申請專利範圍第1項所述之該口服毒物吸附劑之結構,該正電活性竹碳微球結構之粒徑約為100-2000微米。 The structure of the oral poison adsorbent according to claim 1, wherein the positively-active bamboo carbon microsphere structure has a particle diameter of about 100 to 2000 μm. 一種口服毒物吸附劑之結構,係由一海藻酸之生物可蛻化高分子材料包覆一活性竹碳粉末形成一表面官能基帶負電之負電活性竹碳微球結構,其中該活性竹炭粉末與該海藻酸之生物可蛻化高分子材料之混合重量比為1:2至1:5,並經口投吸附腸胃道之毒性物質,再由腸道排出體外。 The structure of an oral poison adsorbent is a negatively active negatively active bamboo carbon microsphere structure formed by coating a living bamboo carbon powder with a biodegradable polymer material of alginic acid, wherein the active bamboo charcoal powder and the active bamboo charcoal powder The alginic acid biodegradable polymer material has a mixing ratio of 1:2 to 1:5, and the toxic substance of the gastrointestinal tract is orally administered, and then excreted from the intestine. 如申請專利範圍第3項所述之該口服毒物吸附劑之結構,該負電活性竹碳微球結構之粒徑約為100-2000微米。 The negatively active bamboo carbon microsphere structure has a particle size of about 100-2000 microns as claimed in claim 3 of the oral toxic adsorbent. 一種口服毒物吸附劑之製造方法,其步驟包括:將一竹材裁切後放入一高溫炭化爐中,真空抽氣;將該竹材置於該高溫炭化爐中,並升溫至400℃至950℃,反應30分鐘至1小時,令該竹材炭化,並於炭化過程中通入一惰性氣體,令該竹材在無氧的環境下燃燒,產生一炭化竹材;將該炭化竹材持續置於該高溫炭化爐中,將該高溫炭化爐之溫度調整在750℃至1000℃進行活性化,並於活性化過程中通入一活化劑,反應1至2小時,進行竹炭活化,產生一活性竹炭;將該活化竹炭冷卻,再用一清洗液並使之乾燥; 將該活性竹炭通過一研磨元件,形成一50微米至1000微米之一活性竹炭粉末;將研磨後之該活性竹炭粉末與一生物可蛻化高分子材料以重量比為1:2至1:5混和;以及將混有該生物可蛻化高分子材料之活性竹炭粉末滴到0.01-10%的交聯溶液中,即製備出直徑大小約100微米至2000微米一活性竹炭微球即為口服毒物吸附劑。 The invention relates to a method for manufacturing an oral poison adsorbent, which comprises the steps of: cutting a bamboo material into a high-temperature carbonization furnace, evacuating the vacuum; placing the bamboo material in the high-temperature carbonization furnace, and heating the temperature to 400 ° C to 950 ° C The reaction is carried out for 30 minutes to 1 hour to carbonize the bamboo material, and an inert gas is introduced into the carbonization process to burn the bamboo material in an oxygen-free environment to produce a carbonized bamboo material; the carbonized bamboo material is continuously placed at the high temperature carbonization. In the furnace, the temperature of the high-temperature carbonization furnace is adjusted to be activated at 750 ° C to 1000 ° C, and an activator is introduced into the activation process for 1 to 2 hours to activate bamboo charcoal to produce an activated bamboo charcoal; Activate bamboo charcoal to cool, then use a cleaning solution and let it dry; Passing the activated bamboo charcoal through a grinding element to form an active bamboo charcoal powder of 50 micrometers to 1000 micrometers; and the weight ratio of the activated bamboo charcoal powder to the biodegradable polymer material after grinding is 1:2 to 1:5 Mixing; and the active bamboo charcoal powder mixed with the biodegradable polymer material is dropped into 0.01-10% of the crosslinking solution to prepare an active bamboo charcoal microsphere having a diameter of about 100 micrometers to 2000 micrometers, which is an oral poison Adsorbent. 如申請專利範圍第5項之口服毒物吸附劑製作方法,其中該惰性氣體係選自氮氣或氬氣之任一種,並以100ml/min至400ml/min之速度通入該高溫炭化爐中。 The method for producing an oral poison adsorbent according to claim 5, wherein the inert gas system is selected from any one of nitrogen gas and argon gas, and is introduced into the high temperature carbonization furnace at a rate of from 100 ml/min to 400 ml/min. 如申請專利範圍第5項之口服毒物吸附劑製作方法,其中該活化劑係選自二氧化碳或水蒸氣之任一種,並以100ml/min至400ml/min之速度通入該高溫炭化爐中。 The method for producing an oral poison adsorbent according to claim 5, wherein the activator is selected from any one of carbon dioxide or water vapor, and is introduced into the high temperature carbonization furnace at a rate of from 100 ml/min to 400 ml/min. 如申請專利範圍第5項之口服毒物吸附劑製作方法,其中該生物可蛻化高分子材料係選自幾丁聚醣、海藻酸、玉米澱粉、甲基纖維素、明膠、褐藻膠、聚糊精等任何天然高分子、天然高分子改良及任何合成高分子單一或任意組成之群組。 The method for preparing an oral toxic adsorbent according to claim 5, wherein the biodegradable polymer material is selected from the group consisting of chitosan, alginic acid, corn starch, methyl cellulose, gelatin, alginate, and polydextrose. Any group of natural polymers, natural polymers, and any single or any combination of synthetic polymers. 如申請專利範圍第8項之口服毒物吸附劑製作方法,其中該生物可蛻化高分子材料為海藻酸與幾丁聚醣,且其海藻酸或幾丁聚醣與竹炭粉末混合重量比為2:1至5:1。 The method for preparing an oral toxic adsorbent according to claim 8 , wherein the biodegradable polymer material is alginic acid and chitosan, and the weight ratio of alginic acid or chitosan to bamboo charcoal powder is 2 : 1 to 5:1.
TW105122361A 2016-07-15 2016-07-15 Oral poison adsorbent and preparation method thereof TWI644686B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW105122361A TWI644686B (en) 2016-07-15 2016-07-15 Oral poison adsorbent and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW105122361A TWI644686B (en) 2016-07-15 2016-07-15 Oral poison adsorbent and preparation method thereof

Publications (2)

Publication Number Publication Date
TW201803552A TW201803552A (en) 2018-02-01
TWI644686B true TWI644686B (en) 2018-12-21

Family

ID=62013934

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105122361A TWI644686B (en) 2016-07-15 2016-07-15 Oral poison adsorbent and preparation method thereof

Country Status (1)

Country Link
TW (1) TWI644686B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115253762A (en) * 2022-08-27 2022-11-01 西畔(北京)信息技术有限责任公司 Active carbon oral pill, preparation device and preparation method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051150A1 (en) * 1999-04-30 2001-12-13 Natarajan Ranganathan Compositions and methods for alleviating symptoms of uremia in patients
TW200517139A (en) * 2003-10-22 2005-06-01 Kureha Chemical Ind Co Ltd Adsorbent for oral administration, and agent for treating or preventing renal or liver disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051150A1 (en) * 1999-04-30 2001-12-13 Natarajan Ranganathan Compositions and methods for alleviating symptoms of uremia in patients
TW200517139A (en) * 2003-10-22 2005-06-01 Kureha Chemical Ind Co Ltd Adsorbent for oral administration, and agent for treating or preventing renal or liver disease

Also Published As

Publication number Publication date
TW201803552A (en) 2018-02-01

Similar Documents

Publication Publication Date Title
CN109078183B (en) Bionic multifunctional nano preparation based on cancer cell membrane and preparation method and application thereof
EP2628483B1 (en) Medical adsorbent and method for producing same
CN110354295A (en) A kind of optical-thermal conversion material and preparation method thereof
Lee et al. Preparation of spherical encapsulation of activated carbons and their adsorption capacity of typical uremic toxins
TW200410715A (en) Adsorbent for oral administration, agent for treating or preventing renal disease, and agent for treating or preventing liver disease
EP2825181A1 (en) Porous carbon particles for use in the treatment or prevention of liver disease
TWI644686B (en) Oral poison adsorbent and preparation method thereof
CN103891784A (en) Bacteriostatic agent for sterilization and disinfection, skin mucosa disinfection fluid and preparation method thereof
CN104784743B (en) A kind of preparation method of the chitosan-based wound dressing of fragrant bacteriostatic
JP5424177B2 (en) Adsorbent for oral administration
TWI341732B (en) Adsorbent for oral administration,agent for treating or preventing renal disease, and
JP4268672B1 (en) Adsorbent for oral administration
WO2018227448A1 (en) Orally-administered poison adsorbent and manufacturing method therefor
JP5985027B2 (en) Method for producing pharmaceutical adsorbent for oral administration
JP5715139B2 (en) Medical preparation capable of specifically adsorbing unwanted molecules present in the digestive tract
CN114209851A (en) Curcumin-silicon oxide nano drug-loading system and preparation method and application thereof
TWI587878B (en) Oral toxic adsorbent
JP2006070047A (en) Adsorbents for oral administration, remedies or prophylactic agent for kidney diseases and remedies or prophylactic agent for liver diseases
CN112891369A (en) Potassium chloride sustained-release tablet prepared by taking crab shell powder and derivative product thereof as auxiliary materials and preparation method
CN106029218B (en) Strength enhanced oral pharmaceutical adsorbents
CN110693849A (en) Preparation method of fluorouracil targeted sustained-release medicament based on ganoderma lucidum spores
RU2159624C1 (en) Means for correcting microbiocenosis
CN116019846B (en) Formula for treating cardiovascular and cerebrovascular diseases and preparation method thereof
CN109200098A (en) A kind of combination medicine inhibiting Multiple drug-resistan Tubercle bacillus
CN114832142B (en) Chitosan composite dressing and preparation method thereof